Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novabupi
- Development stage
- Phase 3
- Lead developer
- Cristália
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular, Subcutaneous, Spinal, Infiltration, Epidural
01
Overview
**Novabupi** is a modified formulation of bupivacaine hydrochloride, a long-acting amide-type local anesthetic with an optimized enantiomeric ratio of S75:R25, developed by Cristália to reduce cardiotoxicity associated with the R-enantiomer while maintaining efficacy. It blocks sodium channels in nerve membranes, preventing depolarization and conduction of nerve impulses for local and regional anesthesia. Primarily used for surgical anesthesia, postoperative pain control, and spinal anesthesia in procedures like lower limb vascular surgery, it offers a sustained release profile in PLGA implants and hyperbaric formulations.
- Brand names
- Novabupi
- Other names
- bupivacaine (S75-R25)
02
Targets
KCNK2 (Potassium channel subfamily K member 2)KCNA5 (Ultra-rapid delayed rectifier potassium channel)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Novabupi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novabupi.